Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 4, 2001, Pages 333-337

  Kjossev, Kirien T ^a   Losanoff, Julian E ^a  

^a MILITARY MEDICAL ACADEMY   (Bulgaria)

Author keywords

9Paclitaxel; Breast cancer; Cardiac toxicity; Doxorubicin; Pharmacokinetics

Indexed keywords

BMS 183061; BMY 45622; CLEMASTINE; DOXORUBICIN; DOXORUBICINOL; HYDROCORTISONE; PACLITAXEL; PREDNISOLONE; RANITIDINE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG EXPOSURE; DRUG INFUSION; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASTECTOMY; MORBIDITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HEART; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; PACLITAXEL; STROKE VOLUME;

EID: 17944371515     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100297     Document Type: Article

References (12)

1. Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer
2. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties?
3. Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin
4. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
5. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
6. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
7. Cardiac function following combination therapy with Taxol and doxorubicin for advanced breast cancer
8. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
9. Phase I trial of Cremophor EL with bolus doxorubicin
10. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdrla P-glycoprotein
11. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice
12. High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma